DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 129 filers reported holding DENALI THERAPEUTICS INC in Q1 2020. The put-call ratio across all filers is 258.00 and the average weighting 1.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2022 | $939,000 | -12.2% | 30,588 | -15.8% | 0.14% | +51.1% |
Q2 2022 | $1,070,000 | +86.4% | 36,341 | +103.6% | 0.09% | +91.8% |
Q1 2022 | $574,000 | -25.2% | 17,850 | +17.4% | 0.05% | -10.9% |
Q3 2021 | $767,000 | +106.7% | 15,200 | +221.1% | 0.06% | +120.0% |
Q2 2021 | $371,000 | -70.8% | 4,734 | -78.7% | 0.02% | -72.5% |
Q1 2021 | $1,271,000 | -14.4% | 22,265 | +25.7% | 0.09% | -9.0% |
Q4 2020 | $1,484,000 | -42.4% | 17,713 | -75.4% | 0.10% | -41.2% |
Q3 2020 | $2,578,000 | +82.6% | 71,937 | +23.2% | 0.17% | +77.1% |
Q2 2020 | $1,412,000 | +5.1% | 58,400 | -23.9% | 0.10% | -9.4% |
Q1 2020 | $1,343,000 | +103.5% | 76,700 | +102.4% | 0.11% | +158.5% |
Q4 2019 | $660,000 | +9.6% | 37,903 | -3.6% | 0.04% | +13.9% |
Q3 2019 | $602,000 | +158.4% | 39,312 | +250.4% | 0.04% | +157.1% |
Q2 2019 | $233,000 | – | 11,220 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Crestline Management, LP | 7,460,732 | $240,012,000 | 28.78% |
Casdin Capital, LLC | 1,500,000 | $48,255,000 | 2.16% |
Flagship Pioneering Inc. | 2,619,968 | $84,284,000 | 1.98% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 38,000 | $8,192,000 | 1.85% |
Yiheng Capital Management, L.P. | 1,014,684 | $32,642,000 | 1.49% |
SECTORAL ASSET MANAGEMENT INC | 207,100 | $6,662,000 | 1.18% |
Artal Group S.A. | 600,000 | $19,302,000 | 0.81% |
GILDER GAGNON HOWE & CO LLC | 2,619,217 | $84,260,000 | 0.78% |
Temasek Holdings (Private) Ltd | 5,369,487 | $172,736,397 | 0.73% |
BRANDYWINE MANAGERS, LLC | 9,601 | $309,000 | 0.53% |